JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
Read original at benzingaStocks · News reference
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses of $(1.93) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 10:31 AM
- Checked
- Jul 30, 2026, 10:31 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Read original at benzingaTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39
Read original at benzingaHC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55
Read original at benzinga